Advertisement
In addition to standard disclosure over wire services, a news release andfinancial statements will be posted on the NUCRYST web site. To listen to thecall live on the Internet, please go to www.nucryst.com.
Advertisement
Thomas E. Gardner, Chairman, President & CEO and Eliot M. Lurier, VicePresident, Finance & Administration and Chief Financial Officer willparticipate on the call.
An audio file of the call will be archived and posted on the NUCRYST website.
NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufacturesand commercializes medical products that fight infection and inflammationusing its patented atomically disordered nanocrystalline silver technology.Smith & Nephew plc sell a range of advanced wound care products under theirActicoat(TM) trade mark: Acticoat(TM) products incorporate NUCRYST'sSILCRYST(TM) coatings and are sold in over 30 countries. NUCRYST is alsodeveloping pharmaceutical products to address medical conditions that arecharacterized by both infection and inflammation. The Company has developedits proprietary nanocrystalline silver in a powder form for use as an activepharmaceutical ingredient, referred to as NPI 32101.
SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.
Acticoat(TM) is a trademark of Smith & Nephew plc
SOURCE NUCRYST Pharmaceuticals Corp.